What is Sales and Marketing Strategy of Boston Scientific Company?

Hospital and ASC procurement drive the core business through a global direct salesforce and specialty clinical reps; distributors extend reach in LATAM, MEA and parts of APAC.

E‑commerce remains limited but is expanding for accessories/consumables via GPO portals and hospital ERPs; digital tendering and virtual in‑servicing are now standard for complex implants.

Distributor-led markets deliver faster unit growth with lower margins; exclusive or preferred distributor agreements exist in select geographies for urology and endoscopy lines.

From direct hospital focus in the 1980s–2000s to therapy ecosystems and regional distributor partnerships in the 2010s; 2020–2025 accelerated omnichannel account management including remote proctoring and digital tendering.

Positioned as an evidence-first medtech leader serving HCPs and hospital administrators with a clean, clinical visual identity and an authoritative, collaborative tone. Customer experience includes 24/7 case coverage, in‑lab specialists, and comprehensive training to support adoption.

Core message links clinical outcomes, workflow efficiency, and economics; marketing emphasizes real-world evidence and cost‑of‑care reduction to align with hospital reimbursement priorities and DRG pressures.

Differentiates via rapid innovation cadence (e.g., Watchman FLX Pro updates, next‑gen EP/CRM platforms, single‑use endoscopy expansion), broad service‑line breadth enabling enterprise deals, and extensive post‑market evidence including randomized and registry data.

Bundles devices with services and analytics to demonstrate total cost of care benefits; economic models and ACE/ASC SKUs respond to outpatient migration and payer cost scrutiny to protect share versus Medtronic, Abbott and single‑use entrants.

Objective: accelerate LAAC adoption in AFib patients contraindicated to long‑term anticoagulation; creative: 'Leave Nothing to Chance' evidence‑forward messaging leveraging PROTECT AF and PINNACLE FLX data; channels: institutional email, cardiology journals, HCP webinars, congress symposia, geo‑targeted digital around centers of excellence; results: double‑digit Watchman revenue growth and increased US EP/interventional cardiologist awareness, helping Cardiology segment outpace market by several hundred basis points.

Objective: position sterile single‑use duodenoscopes for infection control and workflow efficiency; creative: case studies on cross‑contamination risk reduction and total cost models; channels: trade media, hospital C‑suite briefings, ID conferences, procurement webinars; results: measurable share gains in targeted IDN accounts and increased tenders driven by post‑COVID infection control priorities.

Objective: improve referral flow and shorten time‑to‑implant for chronic pain and movement disorder patients; creative: co‑branded patient education, testimonials and outcome data; channels: clinic websites, geofenced paid search/social, referring physician outreach, in‑practice materials; results: higher qualified consults and improved trial‑to‑implant conversion in pilot geographies informing national rollouts.

Objective: drive PAD treatment adoption using data‑driven selection tools; creative: 'Right Therapy, Right Lesion' decision‑algorithm content; channels: TCT/VEITH symposia, hands‑on labs, AR‑enabled training; results: improved account penetration, pull‑through of disposables and strong training efficacy feedback.